(UPDATED) The risk of death following catheter ablation for atrial fibrillation is higher than rates observed in randomized controlled trials, with the majority of deaths occurring not during the procedure but rather in the 30 days after discharge, according to a large analysis of real-world data.
The early mortality rate, defined as death during the initial admission or 30-day readmission period, was 0.46% among more than 60,000 patients treated for A-fib ablation between 2010 and 2015. Moreover, quarterly rates of early mortality after ablation increased over time, increasing from 0.25% in 2010 to 1.35% in 2015 (P < 0.001).
There are some year-to-year fluctuations, but there is a statistically significant trend, said lead investigator Jim Cheung, MD (Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY), in reference to the increase in early mortality. While its certainly concerning, at least we were able to observe that there was a trend toward increasing comorbidity burden among those patients undergoing catheter ablation procedures. If you adjust for this, that trend [of increasing mortality] is attenuated. So, it suggests that its not so much an issue of hospitals or operators doing a worse job with the procedure, but that were ablating sicker and sicker patients.
To TCTMD, Cheung said the overall mortality rate following A-fib ablation was surprising because it is significantly higher than what has been reported in randomized trials. For example, there were no deaths in the pivotal FIRE AND ICE, CASTLE-AF, and CABANA trials, and no deaths reported in other analyses from large, high-volume academic medical centers.
When I first read this paper, my initial reaction was that the findings must be incorrect. Hugh Calkins
In an editorial accompanying the study, Hugh Calkins, MD (Johns Hopkins Hospital, Baltimore, MD), expresses consternation at the real-world mortality rate. When I first read this paper, my initial reaction was that the findings must be incorrect, he writes. I have performed thousands of AF ablation procedures over the past two decades, and I have never had a patient die as a result of the procedure.
Oussama Wazni, MD (Cleveland Clinic, OH), who was not involved in the study but was part of the Cleveland Clinic group that published data on more than 10,000 patients who underwent A-fib ablation, noted that more and more centers with less experience are performing the procedure. This inexperience translates into worse clinical outcomes, he said. In their series, there were no reported deaths when they published their report in early 2019. Inexperienced, or low-volume, centers performing ablation is concerning, but Wazni noted that patients also have a responsibility, noting that they sometimes choose convenience over excellence.
Patients arent doing their part in seeking out the best possible centers, he told TCTMD.
Hospital Volume and Early Mortality
The analysis of the Nationwide Readmissions Database (NRD), which was led by Edward Cheng, MD, PhD (NewYork-Presbyterian/Weill Cornell Medicine), and published October 28, 2019, in the Journal of the American College of Cardiology, identified several predictors of early mortality, among them procedural complications (adjusted OR 4.06; 95% CI 2.40-6.85), congestive heart failure (adjusted OR 2.20; 95% CI 1.20-4.03), and low AF ablation hospital volume (adjusted OR 2.35; 95% CI 1.33-4.15).
Of the 276 patients who died early following catheter ablation of A-fib, 126 died during the index admission and 150 died during the 30-day readmission after ablation. The median time to death was 11.6 days, and those who died were older and had a higher burden of comorbidities, such as congestive heart failure, CAD, and previous placement of a pacemaker, among other conditions. Patients who died early were also less likely to be treated at a higher-volume hospital or academic medical center. Overall, 62.3% of the early deaths after ablation were patients treated at a low-volume center, defined as a hospital that performed less than 21 ablations per year.
Its significant part of the picture, said Cheung. Hospital volume was a very potent predictor of outcomes. That lines up with what has been shown in the past, and it was nice to see it replicated in our analyses.
The rate of procedural complications during the index admission was 6.7%, increasing from 4.8% to 7.4% between 2010 and 2015 (P < 0.001). Perforation and bleeding/vascular complications occurred in 1.9% and 4.3% of treated patients. Like early mortality, the trend toward increased complications over time attenuated after adjusting for age, hospital volume, and patient comorbidities (P = 0.332 for trend).
EP Competency and Standards
Speaking to the volume issue, Cheung said procedural experience is largely focused on fellowships, noting that the American College of Cardiology (ACC)/American Heart Association(AHA)/Heart Rhythm Society recommend a minimum of 50 A-fib ablations (among other procedures) to complete a fellowship in clinical cardiac electrophysiology. To maintain competency after the fellowship, the professional societies recommend doing at least several AF ablation procedures per month.
For Cheung, their research raises the issue about whether or not a firmer recommendation might be necessary, something akin to the clinical competency statement for PCI from the ACC, AHA, and Society for Cardiovascular Angiography and Interventions. He noted, however, they only had access to hospital-level data and not information on individual operators. For that reason, the investigators are unable to precisely say whether the early mortality rate is directly tied to the electrophysiologist. While the operator is a huge component of outcomes, if the patient has a complication there are entire systems of care involved in treatment, including other physicians and nurses.
Our research raises the question, but there are complexities that need to be drilled down deeper so that we know exactly what the issue is, said Cheung. I feel like this is more than just the operator. Part of this is the institution as well.
To TCTMD, Angelo Biviano, MD (Columbia University Irving Medical Center, New York, NY), said outcomes in the real world can differ from those in clinical trials, particularly since the patient populations differ. He agreed with the investigators assessment that the differences in mortality and complications between these two settings are likely the result of increasing comorbidity burden.
As time goes on and you feel more comfortable with the procedure, the referring physicians, as well as those doing the ablation, may take on riskier patients, he said. AF ablation is becoming more mainstream and with that the complication rates can go up.
Additionally, experience is also likely a factor. Unlike in trials, where patients are treated at high-volume academic medical centers, some hospitals and providers dont have the same degree of experience. The question of minimum volume requirements to perform AF ablations is one that needs to be addressed, said Biviano, noting that select structural heart interventions, such as TAVR, have such minimum standards in place. One of the limitations of the present study is that the causes of death are unknown, so a direct link between the ablation and early mortality is not necessarily the case, he added.
Hospital volume was a very potent predictor of outcomes. Jim Cheung
Wazni advised that physicians need to perform at least 50 A-fib ablations annually to main clinical competency. In his opinion, ablation of A-fib has become almost too routine, with operators taking the procedure for granted. For example, catheter ablation is now offered to sicker and sicker patients, such as those with congestive heart failure. While studies have shown that ablation is superior to medical therapy in patients with congestive heart failure, those studies limited the severity of disease with cutoffs based on ejection fraction, he said. The present NRD analysis does not include data on ejection fraction, but congestive heart failure was a leading cause of hospital readmission and a predictor of mortality.
At the Cleveland Clinic, there have been two deaths following A-fib ablation since their series was published, but these two patients were extremely sick, said Wazni. Thus far, clinicians at their center have ablated more than 20,000 patients with A-fib. Were very proud of our outcomes, he said. Now, its hard for others to replicate this because were a very big center and we do a lot of ablations. Its also a matter of [patient] selection. Thats very, very important. Its something that should be taken into consideration.
In his editorial, Calkins also stresses the importance of operator experience. He highlights a 2013 study showing that more than 80% of 93,801 ablations performed between 2000 and 2010 were done by operators doing less than 25 procedures per year. In that study, annual operator volume (less than 25 procedures) and hospital volume (less than 50 procedures) were significantly associated with adverse outcomes.
This latest study by Cheng and colleagues should serve as a wake-up call to all electrophysiologists who perform AF ablation, all cardiologists who refer patients for this procedure, and all patients who are considering undergoing AF ablation. What is clear is that AF ablation is not a benign procedure, and mortality is a very real complication of the procedure, Calkins concludes.
See the rest here:
Deaths After Ablation of Atrial Fibrillation 'Concerning' in Real-World Analysis - TCTMD
- Best 30 Cardiology in Secaucus, NJ with Reviews - YP.com - April 12th, 2018 [April 12th, 2018]
- Cardiology | Weill Cornell Medicine - April 14th, 2018 [April 14th, 2018]
- Cardiology Conferences 2018 | Cardiology Meetings 2018 ... - April 26th, 2018 [April 26th, 2018]
- Dr. Anil Goel, MD - Birmingham, MI - Cardiology & Clinical ... - April 26th, 2018 [April 26th, 2018]
- Clinical Physiology (Cardiology) MSc/PGDip | Middlesex ... - May 15th, 2018 [May 15th, 2018]
- Cardiology Conferences 2018 | Upcoming Cardiology ... - May 16th, 2018 [May 16th, 2018]
- Clinical Cardiology Section | Cleveland Clinic - May 27th, 2018 [May 27th, 2018]
- Journal of Clinical and Experimental Cardiology - Open ... - June 6th, 2018 [June 6th, 2018]
- Cardiology Summit 2018 | Cardiology Conferences | Heart ... - June 23rd, 2018 [June 23rd, 2018]
- Cardiology Clinical and Research Faculty Members ... - June 26th, 2018 [June 26th, 2018]
- Cardiology Conferences 2018 | Cardiology Congress 2018 ... - June 26th, 2018 [June 26th, 2018]
- About Us - New Jersey Cardiology Associates - July 8th, 2018 [July 8th, 2018]
- About Us - Ventura Clinical Trials - August 16th, 2018 [August 16th, 2018]
- Clinical Cardiology Made Ridiculously Simple: Michael A ... - August 22nd, 2018 [August 22nd, 2018]
- Clinical Cardiology - American Society of Preventive Cardiology - October 2nd, 2018 [October 2nd, 2018]
- Heart Surgery Hospital in india | Cardiology Treatment ... - October 7th, 2018 [October 7th, 2018]
- Clinical Cardiology - American Society of Preventive ... - December 3rd, 2018 [December 3rd, 2018]
- Guideline Clinical App - American College of Cardiology - December 7th, 2018 [December 7th, 2018]
- Journal of Clinical and Experimental Cardiology- Open ... - December 12th, 2018 [December 12th, 2018]
- Clinical Cardiology - Baptist Health - December 30th, 2018 [December 30th, 2018]
- Cardiology at Cancun: Topics in Clinical Cardiology - February 5th, 2019 [February 5th, 2019]
- Department of Cardiovascular Medicine, KU School of Medicine - March 10th, 2019 [March 10th, 2019]
- Towards Health Equality: Improving the Management of Cardiovascular Diseases in Women - International Atomic Energy Agency - September 21st, 2019 [September 21st, 2019]
- Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors - TCTMD - September 21st, 2019 [September 21st, 2019]
- DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF - TCTMD - September 21st, 2019 [September 21st, 2019]
- Combining Nature and Technology, Luye Medical and Cleveland Clinic Join to Build a Future Hospital in Shanghai - Yahoo Finance - September 21st, 2019 [September 21st, 2019]
- Will Renal Denervation for Hypertension Rise Again? - Medscape - September 21st, 2019 [September 21st, 2019]
- Obstructive Sleep Apnea, Sleep Symptoms, and their Association with Cardiovascular Disease - DocWire News - September 21st, 2019 [September 21st, 2019]
- CNE expands pulmonary, sleep services with Brigham & Women's physicians - Warwick Beacon - September 21st, 2019 [September 21st, 2019]
- What I Am Most Looking Forward to at TCT 2019 - TCTMD - September 21st, 2019 [September 21st, 2019]
- Serelaxin Not Linked to CV Mortality Reduction in Patients Hospitalized for Acute HF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Sacubitril-Valsartan Not Linked to Lower Hospitalization Risk, CV Death in HFpEF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- FDA clears multiuse angiography systems from Siemens Healthineers - DOTmed HealthCare Business News - September 21st, 2019 [September 21st, 2019]
- Balloon Pulmonary Angioplasty Effective for Chronic Thromboembolic PH - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- RWJBarnabas Health, St. Luke's University Health launch clinical affiliation - FierceHealthcare - September 21st, 2019 [September 21st, 2019]
- Bilirubin: A Novel Indicator of Infective Endocarditis Adverse Outcomes - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS - TCTMD - September 21st, 2019 [September 21st, 2019]
- Community-based Care Model Reduces CVD Risk - Managed Healthcare Executive - September 21st, 2019 [September 21st, 2019]
- American College of Cardiology Steps Up: Equal Pay, Opportunities for All - TCTMD - September 21st, 2019 [September 21st, 2019]
- FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form - AJMC.com Managed Markets Network - September 21st, 2019 [September 21st, 2019]
- A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred - Medscape - September 21st, 2019 [September 21st, 2019]
- Seeking Synergy: Bringing Cardiology into Your Enterprise Imaging Strategy - Health Imaging - September 21st, 2019 [September 21st, 2019]
- TCT 2019 Day Two: Transcatheter Valves, New and Old - TCTMD - September 30th, 2019 [September 30th, 2019]
- Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis - TCTMD - September 30th, 2019 [September 30th, 2019]
- Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival - Diagnostic and Interventional Cardiology - September 30th, 2019 [September 30th, 2019]
- TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3 - TCTMD - September 30th, 2019 [September 30th, 2019]
- Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy... - September 30th, 2019 [September 30th, 2019]
- Off Script: The New Gatekeepers of Procedural Education - TCTMD - September 30th, 2019 [September 30th, 2019]
- Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE - BioSpace - September 30th, 2019 [September 30th, 2019]
- The Heart of the Matter: Cardiovascular Fitness in Horses - United States Eventing Association - September 30th, 2019 [September 30th, 2019]
- Google parent Alphabet hires former FDA head Robert Califf to lead health strategy and policy - FierceHealthcare - September 30th, 2019 [September 30th, 2019]
- Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- AUGUSTUS: Best Benefit With Apixaban, P2Y12 Inhibitor Dual Therapy - Medscape - September 30th, 2019 [September 30th, 2019]
- New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis - Newswise - September 30th, 2019 [September 30th, 2019]
- Dapagliflozin Improves Heart Failure-Related Health Status in HFrEF - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Remote Ischemic Conditioning Did Not Improve 12 Month Clinical Outcomes After STEMI - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Insights from the European Society of Cardiology congress | Speaking of Medicine - PLoS Blogs - September 30th, 2019 [September 30th, 2019]
- Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- AZ's Farxiga gets heart failure prevention okay from FDA - PMLiVE - October 22nd, 2019 [October 22nd, 2019]
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- The Epidemic Of The Metabolic Syndrome Among The Palestinians In The G | DMSO - Dove Medical Press - October 22nd, 2019 [October 22nd, 2019]
- Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosis - PRNewswire - October 22nd, 2019 [October 22nd, 2019]
- Even With Same Diagnosis, Women Get Half the Heart Attack Treatments as Men - AJMC.com Managed Markets Network - October 22nd, 2019 [October 22nd, 2019]
- Eva Dickerman, Andrew Weil - The New York Times - October 22nd, 2019 [October 22nd, 2019]
- EHR vendor Veradigm and partners creating new shared data tools for researchers - Healthcare IT News - October 22nd, 2019 [October 22nd, 2019]
- Evolocumab Well-tolerated as Add-on for Hypercholesterolemia Therapy - DocWire News - October 22nd, 2019 [October 22nd, 2019]
- Deborah Heart and Lung Center announces affiliation with Cleveland Clinic Heart & Vascular Institute - Health Essentials from Cleveland Clinic - October 22nd, 2019 [October 22nd, 2019]
- New Registry to Provide Insight into STEMI Occurrence, Treatment in North India | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- Finding Your Best Fit in Cardiology - TCTMD - October 22nd, 2019 [October 22nd, 2019]
- Cardiology team expands to meet community need - The Union of Grass Valley - October 22nd, 2019 [October 22nd, 2019]
- Cutler Family gifts $15 million to University Hospitals to transform mens health care - Newswise - November 1st, 2019 [November 1st, 2019]
- Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD - TCTMD - November 1st, 2019 [November 1st, 2019]
- Caregiving and the Soul of Medicine - Medscape - November 1st, 2019 [November 1st, 2019]
- STEMI Mortality Unaffected by Weekend, Weeknight, or Holiday Admission in France - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical publishes positive results from the AMBULATE pivotal study Cardiology2.0 - Cardiology2.0 - November 1st, 2019 [November 1st, 2019]
- Gaps in Access to TAVR and SAVR: 'Something Needs to Be Done' - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical... - November 1st, 2019 [November 1st, 2019]
- Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential - 24/7 Wall St. - November 7th, 2019 [November 7th, 2019]
- Global Computed Tomography (CT) Scanners Devices and Equipment Market Report 2020: Major Players are GE Healthcare, Koninklijke Philips, Hitachi,... - November 7th, 2019 [November 7th, 2019]
- Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD - TCTMD - November 7th, 2019 [November 7th, 2019]